Haihong Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Haihong Fang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Lulan Li
Department of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Peoples Republic of China
2 shared publications- Zhenhua Zeng
Department of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 shared publications Fengfan Xia
Department of Cardiology Shunde Hospital Southern Medical University (The First People’s Hospital of Shunde Foshan) Foshan 528300 Guangdong China fimmu.com
1 shared publication- Hong Yang
Department of Critical Care Medicine, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China
1 shared publication Jiancheng Wang
Department of Intensive Care Unit, The Third Affiliated Hospital of Southern Medical University, Guangzhou 510630, Peoples Republic of China
1 shared publication- Jie Wu
Department of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
1 shared publication
Latest Publications
- 25 August 2026
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 49 (8) , 1073-1102
Dexmedetomidine attenuates sepsis-associated NET formation and Th17 polarization through α2-adrenergic receptor-associated regulation of hepatic HPD
- 25 August 2026
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 49 (8) , 1073-1102
Dexmedetomidine attenuates sepsis-associated NET formation and Th17 polarization through α2-adrenergic receptor-associated regulation of hepatic HPD
- Open Access
- 30 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1646413
Editorial: Mitochondrial damage interacts with the immune system and tumor microenvironment
Despite the clinical success of immunotherapy in certain cancers, patient sensitivity and resistance remain persistent challenges. As the primary energy powerhouses of eukaryotic cells, mitochondria exhibit dysfunction and metabolic perturbations that alter endogenous molecular expression (1,2). Mitochondria also extensively participate in emerging cell death processes such as ferroptosis and cuproptosis, consequently reshaping the infiltration and functional state of tumor immune cells. Exploring mitochondria-associated targets and their crosstalk with cell death pathways represents a potential approach to overcome immunotherapy resistance.
- 30 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1646413
Open AccessEditorial: Mitochondrial damage interacts with the immune system and tumor microenvironment
Despite the clinical success of immunotherapy in certain cancers, patient sensitivity and resistance remain persistent challenges. As the primary energy powerhouses of eukaryotic cells, mitochondria exhibit dysfunction and metabolic perturbations that alter endogenous molecular expression (1,2). Mitochondria also extensively participate in emerging cell death processes such as ferroptosis and cuproptosis, consequently reshaping the infiltration and functional state of tumor immune cells. Exploring mitochondria-associated targets and their crosstalk with cell death pathways represents a potential approach to overcome immunotherapy resistance.
- 1 December 2021
- Published by Elsevier in International Immunopharmacology
- Vol. 101 (Pt B) , 108331
Remimazolam reduces sepsis-associated acute liver injury by activation of peripheral benzodiazepine receptors and p38 inhibition of macrophages
- 1 December 2021
- Published by Elsevier in International Immunopharmacology
- Vol. 101 (Pt B) , 108331
Remimazolam reduces sepsis-associated acute liver injury by activation of peripheral benzodiazepine receptors and p38 inhibition of macrophages
- RetractedOpen Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
[Retracted] Novel Insights into the Molecular Features and Regulatory Mechanisms of Mitochondrial Dynamic Disorder in the Pathogenesis of Cardiovascular Disease
Mitochondria maintain mitochondrial homeostasis through continuous fusion and fission, that is, mitochondrial dynamics, which is precisely mediated by mitochondrial fission and fusion proteins, including dynamin‐related protein 1 (Drp1), mitofusin 1 and 2 (Mfn1/2), and optic atrophy 1 (OPA1). When the mitochondrial fission and fusion of cardiomyocytes are out of balance, they will cause their own morphology and function disorders, which damage the structure and function of the heart, are involved in the occurrence and progression of cardiovascular disease such as ischemia‐reperfusion injury (IRI), septic cardiomyopathy, and diabetic cardiomyopathy. In this paper, we focus on the latest findings regarding the molecular features and regulatory mechanisms of mitochondrial dynamic disorder in cardiovascular pathologies. Finally, we will address how these findings can be applied to improve the treatment of cardiovascular disease.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
RetractedOpen Access[Retracted] Novel Insights into the Molecular Features and Regulatory Mechanisms of Mitochondrial Dynamic Disorder in the Pathogenesis of Cardiovascular Disease
Mitochondria maintain mitochondrial homeostasis through continuous fusion and fission, that is, mitochondrial dynamics, which is precisely mediated by mitochondrial fission and fusion proteins, including dynamin‐related protein 1 (Drp1), mitofusin 1 and 2 (Mfn1/2), and optic atrophy 1 (OPA1). When the mitochondrial fission and fusion of cardiomyocytes are out of balance, they will cause their own morphology and function disorders, which damage the structure and function of the heart, are involved in the occurrence and progression of cardiovascular disease such as ischemia‐reperfusion injury (IRI), septic cardiomyopathy, and diabetic cardiomyopathy. In this paper, we focus on the latest findings regarding the molecular features and regulatory mechanisms of mitochondrial dynamic disorder in cardiovascular pathologies. Finally, we will address how these findings can be applied to improve the treatment of cardiovascular disease.